Literature DB >> 15625620

Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation.

Kenneth E White1, Jose M Cabral, Siobhan I Davis, Tonya Fishburn, Wayne E Evans, Shoji Ichikawa, Joanna Fields, Xijie Yu, Nick J Shaw, Neil J McLellan, Carole McKeown, David Fitzpatrick, Kai Yu, David M Ornitz, Michael J Econs.   

Abstract

Activating mutations in the genes for fibroblast growth factor receptors 1-3 (FGFR1-3) are responsible for a diverse group of skeletal disorders. In general, mutations in FGFR1 and FGFR2 cause the majority of syndromes involving craniosynostosis, whereas the dwarfing syndromes are largely associated with FGFR3 mutations. Osteoglophonic dysplasia (OD) is a "crossover" disorder that has skeletal phenotypes associated with FGFR1, FGFR2, and FGFR3 mutations. Indeed, patients with OD present with craniosynostosis, prominent supraorbital ridge, and depressed nasal bridge, as well as the rhizomelic dwarfism and nonossifying bone lesions that are characteristic of the disorder. We demonstrate here that OD is caused by missense mutations in highly conserved residues comprising the ligand-binding and transmembrane domains of FGFR1, thus defining novel roles for this receptor as a negative regulator of long-bone growth.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15625620      PMCID: PMC1196382          DOI: 10.1086/427956

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  30 in total

1.  Receptor for acidic fibroblast growth factor is related to the tyrosine kinase encoded by the fms-like gene (FLG).

Authors:  M Ruta; W Burgess; D Givol; J Epstein; N Neiger; J Kaplow; G Crumley; C Dionne; M Jaye; J Schlessinger
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

2.  Fibroblast growth factor receptor 2 mutations in Beare-Stevenson cutis gyrata syndrome.

Authors:  K A Przylepa; W Paznekas; M Zhang; M Golabi; W Bias; M J Bamshad; J C Carey; B D Hall; R Stevenson; S Orlow; M M Cohen; E W Jabs
Journal:  Nat Genet       Date:  1996-08       Impact factor: 38.330

3.  Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome.

Authors:  Catherine Dodé; Jacqueline Levilliers; Jean-Michel Dupont; Anne De Paepe; Nathalie Le Dû; Nadia Soussi-Yanicostas; Roney S Coimbra; Sedigheh Delmaghani; Sylvie Compain-Nouaille; Françoise Baverel; Christophe Pêcheux; Dominique Le Tessier; Corinne Cruaud; Marc Delpech; Frank Speleman; Stefan Vermeulen; Andrea Amalfitano; Yvan Bachelot; Philippe Bouchard; Sylvie Cabrol; Jean-Claude Carel; Henriette Delemarre-van de Waal; Barbara Goulet-Salmon; Marie-Laure Kottler; Odile Richard; Franco Sanchez-Franco; Robert Saura; Jacques Young; Christine Petit; Jean-Pierre Hardelin
Journal:  Nat Genet       Date:  2003-03-10       Impact factor: 38.330

4.  Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome.

Authors:  O A Ibrahimi; A V Eliseenkova; A N Plotnikov; K Yu; D M Ornitz; M Mohammadi
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-05       Impact factor: 11.205

5.  A novel mutation in FGFR-3 disrupts a putative N-glycosylation site and results in hypochondroplasia.

Authors:  A Winterpacht; K Hilbert; C Stelzer; T Schweikardt; H Decker; H Segerer; J Spranger; B Zabel
Journal:  Physiol Genomics       Date:  2000-01-24       Impact factor: 3.107

6.  Stat1 controls postnatal bone formation by regulating fibroblast growth factor signaling in osteoblasts.

Authors:  Liping Xiao; Takahiro Naganawa; Eneze Obugunde; Gloria Gronowicz; David M Ornitz; J Douglas Coffin; Marja M Hurley
Journal:  J Biol Chem       Date:  2004-04-08       Impact factor: 5.157

7.  Osteoglophonic dwarfism.

Authors:  P Beighton; B J Cremin; K Kozlowski
Journal:  Pediatr Radiol       Date:  1980-09

Review 8.  Fibroblast growth factors.

Authors:  D M Ornitz; N Itoh
Journal:  Genome Biol       Date:  2001-03-09       Impact factor: 13.583

9.  FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting.

Authors:  Mara Riminucci; Michael T Collins; Neal S Fedarko; Natasha Cherman; Alessandro Corsi; Kenneth E White; Steven Waguespack; Anurag Gupta; Tamara Hannon; Michael J Econs; Paolo Bianco; Pamela Gehron Robey
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

10.  Two FGF receptor genes are differentially expressed in epithelial and mesenchymal tissues during limb formation and organogenesis in the mouse.

Authors:  K G Peters; S Werner; G Chen; L T Williams
Journal:  Development       Date:  1992-01       Impact factor: 6.868

View more
  108 in total

Review 1.  Biology of Fibroblast Growth Factor 23: From Physiology to Pathology.

Authors:  Marie Courbebaisse; Beate Lanske
Journal:  Cold Spring Harb Perspect Med       Date:  2018-05-01       Impact factor: 6.915

Review 2.  The expanding family of hypophosphatemic syndromes.

Authors:  Thomas O Carpenter
Journal:  J Bone Miner Metab       Date:  2011-12-14       Impact factor: 2.626

Review 3.  Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism.

Authors:  L Darryl Quarles
Journal:  Nat Rev Endocrinol       Date:  2012-01-17       Impact factor: 43.330

Review 4.  Single-spanning transmembrane domains in cell growth and cell-cell interactions: More than meets the eye?

Authors:  Pierre Hubert; Paul Sawma; Jean-Pierre Duneau; Jonathan Khao; Jérôme Hénin; Dominique Bagnard; James Sturgis
Journal:  Cell Adh Migr       Date:  2010-04-20       Impact factor: 3.405

5.  Unliganded fibroblast growth factor receptor 1 forms density-independent dimers.

Authors:  Laëtitia Comps-Agrar; Diana Ronai Dunshee; Dan L Eaton; Junichiro Sonoda
Journal:  J Biol Chem       Date:  2015-08-13       Impact factor: 5.157

Review 6.  FGF23 and Phosphate Wasting Disorders.

Authors:  Xianglan Huang; Yan Jiang; Weibo Xia
Journal:  Bone Res       Date:  2013-06-28       Impact factor: 13.567

Review 7.  Role of receptor tyrosine kinase transmembrane domains in cell signaling and human pathologies.

Authors:  Edwin Li; Kalina Hristova
Journal:  Biochemistry       Date:  2006-05-23       Impact factor: 3.162

Review 8.  DIAGNOSIS OF ENDOCRINE DISEASE: Mosaic disorders of FGF23 excess: Fibrous dysplasia/McCune-Albright syndrome and cutaneous skeletal hypophosphatemia syndrome.

Authors:  Luis F de Castro; Diana Ovejero; Alison M Boyce
Journal:  Eur J Endocrinol       Date:  2020-05       Impact factor: 6.664

Review 9.  Kinase mutations in human disease: interpreting genotype-phenotype relationships.

Authors:  Piya Lahiry; Ali Torkamani; Nicholas J Schork; Robert A Hegele
Journal:  Nat Rev Genet       Date:  2010-01       Impact factor: 53.242

10.  FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1.

Authors:  Jyothsna Gattineni; Carlton Bates; Katherine Twombley; Vangipuram Dwarakanath; Michael L Robinson; Regina Goetz; Moosa Mohammadi; Michel Baum
Journal:  Am J Physiol Renal Physiol       Date:  2009-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.